Moxicum

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moxicum

Property Description
Active ingredient Moxifloxacin (as hydrochloride salt)
Form Film-coated tablet, intravenous infusion, ophthalmic solution
Pharmacological class Fluoroquinolone Antibiotic (Fourth Generation)
General purpose To kill susceptible bacteria causing infection
Origin Synthetic (chemically synthesized)
Prescription Status Prescription-only medicine (Rx)

What is Moxicum and What Type of Antibiotic Is It?

Moxicum is a prescription-only medicine (Rx) containing the active ingredient Moxifloxacin, which is recognized as a potent, broad-spectrum fluoroquinolone antibiotic. This drug is a synthetic compound derived from quinolone carboxylic acid and is a member of the fourth generation of the quinolone family. This particular generation is clinically recognized for its superior activity against certain bacteria, a key feature that differentiates it from older quinolone compounds. Moxifloxacin is effective against a wide range of bacterial infections.

Its classification as a fluoroquinolone is crucial because its chemical structure is designed to be highly effective against many types of bacteria, including some that might be resistant to older antibiotic classes. Its primary role is to provide systemic or topical treatment to eliminate the pathogens responsible for an illness, such as a localized bacterial eye infection, which represents a typical use scenario for one of its specific dosage forms.


Composition, Forms, and General Purpose

Moxicum is a single active ingredient product, consisting solely of Moxifloxacin. A key differentiating factor is its versatility in pharmaceutical preparations to ensure the medicine can effectively reach different infection sites. These forms include a standard film-coated tablet for oral ingestion, a sterile solution for intravenous infusion for delivery in clinical settings, and an ophthalmic solution (eye drops) for topical use. Moxifloxacin is used both orally and as an eye drop, indicating its formulation is robust for different types of bacterial infections. The medicine's overall therapeutic value lies in its bactericidal action: it is specifically designed to kill bacterial cells and help the body clear the infection completely.

Regulatory References

  1. NIH Drug Information
  2. MedlinePlus Drug Info

What side effects are possible with Moxicum?

Possible side effects and safety information

The safety profile for Moxicum (Moxifloxacin) is formally defined by official regulatory classifications that group possible adverse reactions by frequency and affected body system. This structure clarifies the officially documented risks without providing clinical guidance.

Frequency-Classified Adverse Reactions

The adverse reactions are categorized based on their incidence as documented in regulatory sources:

  • Common (affecting 1 to 10 users in 100): Gastrointestinal effects such as nausea, diarrhea, vomiting, and abdominal pain; headache, dizziness, and documented elevations in liver enzymes.
  • Uncommon (affecting 1 to 10 users in 1,000): Hypoglycemia, allergic reactions, sleep disturbances, tremors, palpitations, and initial signs of musculoskeletal or nervous system effects like tendinitis and peripheral neuropathy.
  • Rare and Very Rare: Include psychotic reactions, depression, severe cutaneous adverse reactions, and specific serious events.

Serious Adverse Reactions and Safety Constraints

The official labeling explicitly notes potentially disabling and irreversible serious adverse reactions. These primarily affect the nervous, musculoskeletal, and cardiovascular systems and include:

  • Tendon Rupture (most commonly Achilles tendon), which can occur during treatment or up to several months after cessation.
  • Peripheral Neuropathy (nerve damage) with rapid onset.
  • Aortic Aneurysm and Dissection and QT Interval Prolongation, which may lead to life-threatening heart rhythm issues.

Safety notes specify higher risk in certain populations, such as older adults (increased risk of tendon rupture) and diabetic patients (increased risk of severe hypoglycemia). Furthermore, official constraints state the drug should not be used in individuals with a history of quinolone-related tendon disorders or severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information indicates that no specific symptoms of acute overdose in humans are documented for moxifloxacin. Overdosing is expected to lead to an exaggeration of the known adverse effects of the medication.

Overdose-related risk focuses on several key systems, including the cardiovascular system, the central nervous system, and the gastrointestinal tract. The main risk factor specifically highlighted in official labeling is the potential for QT interval prolongation, a serious electrical disturbance of the heart rhythm.

Required Emergency Actions

In the event of a suspected or confirmed acute overdose, immediate medical help must be sought (call emergency services or Poison Control). The official procedural recommendations are centered on supportive care and the elimination of the drug from the body:

  • Maintain adequate hydration of the patient.
  • ECG monitoring is recommended for continuous observation of the heart’s electrical activity due to the risk of QT prolongation.
  • The administration of activated charcoal as soon as possible after oral overdose may help prevent excessive increase in the drug's systemic exposure.
  • Standard procedures like hemodialysis or continuous ambulatory peritoneal dialysis remove only a small percentage (about 3% to 9%) of the drug, meaning these are generally not effective primary treatments for overdose.

The patient should be carefully observed and given comprehensive supportive treatment in a medical setting.

Therapeutic Uses of Moxicum

Moxicum (Moxifloxacin) is an antibiotic applied across domains where additional symptomatic support is needed, addressing symptoms related to systemic imbalance in situations involving certain distressing symptoms. Its therapeutic applications include specific respiratory, skin, and abdominal infections.

The medication is commonly used across conditions presenting with acute episodes, including bacterial infections of the lower airways such as Community-Acquired Pneumonia and Acute Bacterial Exacerbations of Chronic Bronchitis, as well as complicated infections of the skin, soft tissues, and abdomen. It helps address symptom clusters that may appear suddenly and create noticeable physiological strain.

“The treatment is generally relevant in clinical contexts that involve acute or unstable symptom patterns, where supportive symptom management is appropriate.”

Systemically, Moxicum is relevant for managing drug-resistant pathogens and specialized infections, supporting patients during difficult episodes by easing distress. In its topical form, it assists with localized symptomatic relief from bacterial conjunctivitis (pinkeye). The overall benefit contributes to easing the impact on daily comfort and assists with maintaining functional stability during periods of heightened infectious symptoms.


Quick Fact: Symptomatic Support in Respiratory and Systemic Domains

Eligibility and Restrictions for Use

Who Can and Cannot Use Moxicum? (Moxifloxacin)

Official regulatory information defines specific populations eligible for Moxicum (systemic formulations) and those for whom use is strictly prohibited (contraindicated).

Eligibility by Age Group

Moxicum systemic formulations are indicated only for adults (ge 18 years of age). The medicine is contraindicated in children and adolescents (lt 18 years). While geriatric patients do not require a dosage adjustment based on age alone, they may have increased risk factors requiring caution.

Absolute Contraindications

The medicine is contraindicated and must not be used in patients with:

  • A known hypersensitivity to moxifloxacin, other quinolone antibiotics, or any component of the formulation.
  • A history of tendon disorder or rupture related to previous quinolone treatment.
  • Documented or congenital QT interval prolongation, uncorrected low potassium levels (hypokalaemia), or clinically relevant bradycardia or heart failure.
  • Severe hepatic impairment (Child-Pugh C).

Pregnancy and Restricted Use

Systemic use is contraindicated during both pregnancy and lactation/breastfeeding. Use requires caution in patients with disorders like Myasthenia Gravis (use should be avoided), Central Nervous System (CNS) disorders, or those taking corticosteroids who are at increased risk of tendon rupture. No dosage adjustment is required for patients with mild to severely impaired renal function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Moxicum (Moxifloxacin) has an officially defined interaction profile structured around critical pharmacokinetic and pharmacodynamic restrictions, as documented in regulatory labeling.

Contraindicated Combinations and Cardiac Risk

Co-administration is formally contraindicated with Class IA and Class III Antiarrhythmics (such as quinidine and sotalol). This restriction is based on a documented enhanced pharmacodynamic risk of QT interval prolongation and potential serious ventricular arrhythmias. Avoidance is also required for other medicines officially known to prolong the QT interval.

Pharmacokinetic and Timing Restrictions

The systemic exposure of oral Moxicum is significantly reduced when taken with multivalent cation-containing products (e.g., antacids, sucralfate, or iron supplements). To mitigate this pharmacokinetic interference, a mandatory timing separation is required: Moxicum must be administered at least 4 hours before or 8 hours after these products.

Specific Pharmacodynamic Risks

Documented pharmacodynamic interactions include an officially noted enhanced anticoagulant effect when co-administered with Warfarin. Use with Corticosteroids is also officially linked to an increased risk of tendinitis and tendon rupture, a risk heightened in older patients. The drug is officially stated not to interact via the major CYP450 enzyme system.

Mechanism of Action

How Moxicum Works

The action of Moxicum (Moxifloxacin) is defined by its selective inhibition of enzymes essential for bacterial DNA replication. The drug exerts a bactericidal effect by targeting essential enzymes unique to the bacterial cell.


Dual-Targeting of Essential Bacterial Enzymes

Moxicum acts as an inhibitor by simultaneously binding to two critical enzymes within the bacterial cell: DNA Gyrase (Topoisomerase II) and Topoisomerase IV. This dual inhibition stabilizes the complex, preventing the enzymes from resealing the double-strand DNA breaks and disrupting the structural integrity and division of the bacterial chromosome.


Initiation of the Pathogen Cell Death Cascade

The accumulation of double-strand DNA damage triggers the bacterium's internal response, leading to autolysis (cell self-destruction). This process initiates a cellular-level cascade resulting in the physiological collapse and death of the susceptible pathogen. This mechanism establishes the drug's bactericidal action against susceptible pathogens.


Constraints on Mechanistic Efficacy

The mechanism is constrained by bacterial defense strategies, namely mutations in the enzyme target sites and the expression of efflux pumps. These pumps actively transport Moxicum out of the bacterial cell, leading to reduced drug concentration at the DNA targets, which limits the initiation of the cell death cascade.

Dosage and Administration Information

How to Use Moxicum: Administration Guidelines

Administration of Moxicum (Moxifloxacin) is governed by protocols that define the specific routes, standardized doses, and timing for its use.


Administration Scope

Feature Guideline
Route of Administration Oral (film-coated tablet), Intravenous (IV) (solution for infusion), and Topical Ophthalmic (eye drops).
Dosing Schedule The standard dose for all systemic (oral and IV) administration is 400 mg once daily; this maximum daily dose should not be exceeded.
Timing in relation to meals Oral tablets may be taken independently of meals (with or without food).
Preparation Requirements Intravenous solution must be infused over a period of 60 minutes (1 hour). Oral tablets are to be swallowed whole with liquid.
Special Populations No dosage adjustment is required for older adults or in cases of severe renal impairment.
Missed-Dose Rule A missed oral dose should be taken if the next scheduled dose is more than 8 hours away.

Resulting Procedural Structure

The treatment course is delivered once daily for systemic use, with the total duration ranging from approximately 5 to 21 days, depending on the specific condition being addressed. For example, courses may span 7 days for Acute Bacterial Sinusitis or up to 10 days for Community-Acquired Pneumonia, or longer for sequential IV-to-oral therapy, as defined in the prescribing information. The topical ophthalmic form is used on a multiple-times-daily basis (2-3 times) and is strictly for the eye, not for injection. This protocol ensures a uniform approach to administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moxicum


Evidence for Use in Respiratory Tract Infections

Moxicum (Moxifloxacin) was studied in numerous randomized controlled trials (RCTs) and systematic reviews, where researchers explored the medicine's measured outcomes related to Community-Acquired Pneumonia (CAP) and Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB). These studies included adults, often encompassing older adults, who presented with symptoms of acute infection and physiological strain. Research often utilized a non-inferiority design, with trials set up using an active-controlled design where outcomes measured were compared against other study agents.

The study outcomes examined in these large trials included measures of clinical response (assessing changes in symptoms and signs) and bacteriological response, which tracked the presence of targeted bacteria in cultures. Findings so far describe patterns of clinical response and microbiological outcomes that were observed across various study groups. For ABECB, specific studies monitored outcomes related to the time until subsequent infectious episodes occurred.


Evidence for Use in Complex Systemic Infections

Research explored the measured outcomes related to Moxicum in complex and widespread conditions, such as Complicated Skin and Soft Tissue Infections (cSSSI) and Complicated Intra-Abdominal Infections (cIAI). These conditions are characterized by fluctuating or episodic manifestations and require therapy that addresses outcomes related to physiological function or overall clinical status. Studies in this area included randomized trials examining Moxicum, sometimes used as monotherapy, against combination antibiotic treatments.


What is Still Uncertain About Moxicum Research

While Moxicum was evaluated in extensive clinical trials, several areas of uncertainty remain. Many major studies were designed using a non-inferiority approach, which aims to determine if measured outcomes are comparable to an existing treatment, rather than designed to show definitive superiority. Comparative evidence is lacking in some areas against every available treatment option. Furthermore, evidence quality varies across studies, and findings were sometimes mixed regarding the specific patterns of outcomes measured against various comparators. Data characterizing prolonged clinical patterns following the study period remain limited.

Key Studies & References

  1. Moxifloxacin in the treatment of acute bacterial rhinosinusitis: results of a multicenter, non-interventional study

Frequently Asked Questions (FAQ)

Common questions about Moxicum (FAQ)


Q: What is the typical time frame for the duration of Moxicum's effect?

The duration of the drug’s presence in the body is measured by its elimination half-life, which is the time it takes for half of the drug to be processed and removed. Official pharmacokinetic data indicates that the elimination half-life of Moxicum is approximately 12.1 hours.

Q: How long does Moxicum stay in your system after the last dose?

Pharmacokinetic data from official sources describes how the body eliminates Moxicum. The drug's elimination half-life is approximately 12.1 hours, meaning it takes this amount of time for the concentration in the body to drop by half after the final dose.

Q: How is Moxicum processed by the body?

Pharmacokinetic reviews explain that Moxicum is extensively absorbed from the digestive system. The drug is processed (metabolized) in the liver primarily through a process known as conjugation. From there, approximately 45% of the dose is excreted from the body in an unchanged form via urine and feces.

Q: Is Moxicum the same as its generic version?

Yes, the generic version, which is Moxifloxacin Hydrochloride, is considered the same for treatment purposes. Regulatory agencies, such as the FDA, have determined that the generic formulation is bioequivalent and therefore considered therapeutically equivalent to the brand-name product.

Q: What is the difference between the immediate-release and extended-release forms of Moxicum?

The standard dosage form of Moxicum approved for systemic use is the immediate-release oral tablet. Official product information for the most commonly prescribed versions does not typically include an extended-release formulation.

Q: Is it okay to take Moxicum with vitamins?

Vitamins containing specific ingredients, known as polyvalent cations (such as calcium, iron, or magnesium), can interfere with how the body absorbs Moxicum. Regulatory documents describe a mandatory timing separation to mitigate this effect. These vitamins should be taken several hours before or after Moxicum to minimize this impact.

Q: Are there any specific supplements or herbal products that should be avoided with Moxicum?

Yes, there is regulatory guidance regarding supplements containing multivalent cations, such as iron, calcium, magnesium, or zinc. These products can interfere with the way Moxicum is absorbed into the bloodstream. Official guidance notes that the administration of these supplements should be separated from Moxicum by a few hours.

Q: Does Moxicum have any restrictions related to caffeine intake?

Regulatory product information does not typically impose specific restrictions regarding caffeine intake while taking Moxicum. This is because Moxicum is processed by the body differently than some older quinolone antibiotics, which were known to slow down the body’s ability to clear caffeine.

Q: Does Moxicum interact with common over-the-counter pain medications?

Official regulatory information indicates that certain common Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may increase the risk of neuroexcitatory activities when taken with Moxicum. Additionally, the body's processing (metabolism) of Acetaminophen may be affected.

Q: Can Moxicum affect dental procedures or bleeding?

Official documents describe an interaction where Moxicum can enhance the anticoagulant effects of blood thinning medicines like Warfarin. This interaction leads to an increased risk of bleeding, which may manifest as bleeding gums or nosebleeds. Regulatory information notes that close monitoring of clotting time is described for patients taking anticoagulants.

Q: Can Moxicum be taken by people who have high blood pressure?

The official regulatory labels do not typically list pre-existing high blood pressure, or hypertension, as a specific formal contraindication for Moxicum use. However, hypertension itself is documented as an uncommon side effect that has occurred in some patients.

Q: Is Moxicum known to cause anxiety or mood changes?

Yes, according to official product information, psychiatric reactions are documented adverse effects of Moxicum. These reactions can include anxiety, depression, confusion, and disorientation. Official guidance recommends that changes in mood or behavior be discussed immediately with a healthcare provider.

Q: Is Moxicum linked to any hearing or vision problems?

According to official product labeling, visual disturbances are listed as an uncommon side effect. While not common, transient loss of vision has been reported in very rare cases with other medicines in the same class (fluoroquinolones).

Q: Can Moxicum affect my ability to drive or operate machinery?

Official product labels confirm that Moxicum can affect a person's ability to safely drive or operate heavy machinery. This is due to potential side effects, such as dizziness or confusion. The medicine may also rarely cause a temporary loss of consciousness, known as syncope.

Q: What are the signs of a serious allergic reaction to Moxicum?

Signs of a serious allergic reaction are detailed in the official medication guide and may include severe symptoms like difficulty breathing, the presence of hives, or swelling of the face, tongue, or throat. Serious skin reactions have also been reported. Official regulatory guidance describes that these symptoms require immediate medical attention.

Q: Is Moxicum safe to use for a long period of time?

Official regulatory communications have noted that Moxicum, like other drugs in its class, carries a warning about potentially disabling and irreversible serious adverse reactions. These effects involve multiple body systems, including the musculoskeletal, nervous, and psychiatric systems. These reactions may be prolonged, sometimes continuing for months or years, regardless of how long the medicine was taken.

Q: What happens if I stop taking Moxicum suddenly?

Stopping the medicine before completing the full duration of the prescribed course is associated with documented outcomes. According to regulatory guidance, this action can increase the potential for the bacteria to develop resistance to Moxicum, resulting in the medicine being less effective for future infections.

Q: Does Moxicum need to be taken at the exact same time every day?

Moxicum is designed for a once-daily dosing schedule. Regulatory guidance stresses the importance of taking the medicine regularly throughout the course of treatment. This consistency is essential because skipping doses can increase the potential for bacterial resistance and reduce the drug’s ability to treat the infection effectively.

Q: Are there any routine tests that are needed while taking Moxicum?

Official warnings indicate that while routine tests are not required for every patient, certain groups do require monitoring. Specifically, official warnings state that close monitoring of ECG and serum potassium levels is described for patients at risk for QT prolongation (a change in heart rhythm) due to existing conditions or other medicines they are taking.

How should Moxicum be stored and disposed of?

Moxicum (meloxicam) should be stored in its original container, tightly closed, and kept out of the reach of children and pets. The optimal storage temperature is room temperature, typically between 68 F and 77 F (20 C and 25 C).

Protect the medication from excessive heat, moisture, and light; therefore, it should not be stored in a bathroom.

Disposal Guidelines

When disposing of unused or expired Moxicum, do not flush it down a toilet or pour it down a sink unless specifically instructed by the medication guide or a healthcare professional. Instead, the best method for disposal is often a drug take-back program.

  • Preferred: Use a community drug take-back location or a mail-back program, if available.
  • Alternative: If a take-back program is unavailable, mix the medication with an unappealing substance, such as dirt or used coffee grounds. Place the mixture in a sealed bag or container and dispose of it in the household trash. Always obscure or remove personal information from the prescription label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moxicum found in:

A-Z Index: